Stable phentolamine mesylate inhalation liquid preparation and preparation method thereof
By adding isotonic agent and metal ion complex to the liquid preparation of phentolamine methanesulfonate inhalation, and preparing by multiple filter membrane filtration and sterile environment, phentolamine methanesulfonate in the prior art has been solved. Adverse reactions and stability problems of injections have achieved efficient targeted treatment and commercial production.
Patent Information
- Application Number
- CN202410930060.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-05
AI Technical Summary
The existing phentolamine methanesulfonate injection has not undergone rigorous pharmacological research on inhalation preparations. It may cause adverse reactions such as mucosal damage and airway spasm after atomization and inhalation. It lacks inhaled liquid preparations with good stability, making it difficult to meet clinical needs. .
Using a stable formulation of phentolamine methanesulfonate inhalation liquid formulation, including phentolamine methanesulfonate, isotonic agent, metal ion complex and pH regulator, filtering through multiple filter membranes and sterile environments Prepare under the preparation to avoid high-temperature steam sterilization and ensure the reproducibility and stability of the preparation process.
It significantly reduces the adverse reaction rate of medication, improves the quality and storage stability of drugs, and achieves efficient targeted treatment of phentoramine methanesulfonate and commercial large-scale production.
Smart Images

Figure BDA0004939363020000041 
Figure BDA0004939363020000042 
Figure BDA0004939363020000051
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a stable phentolamine mesylate inhalation liquid preparation and a preparation method thereof. Background Art
[0002] Pulmonary inhalation preparations refer to preparations in which drugs are administered by special devices to exert systemic or local effects in the deep respiratory tract, cavity, mucosa, etc. Compared with traditional methods of administration, pulmonary administration has the advantages of being fast, efficient, and having good patient compliance. It is currently recognized in the world as the best method for treating respiratory system diseases. At present, the 2020 edition of the "Chinese Pharmacopoeia" divides inhalation preparations into aerosols, inhalation powder aerosols, inhalation sprays, inhalation liquid preparations, and preparations that can be converted into steam. Among them, inhalation liquid preparations refer to liquid preparations for nebulizers, that is, emulsions, suspensions or solutions that produce continuous aerosols for inhalation through nebulizers. Inhalation liquid administration can atomize suspensions or solutions containing drugs into large doses of small droplets, and is not affected by the patient's breathing behavior. It has a wide range of applications and can be used by children and the elderly.
[0003] Phentolamine mesylate was originally developed by Novartis. It is an α-receptor blocker that rapidly dilates peripheral blood vessels by blocking α-receptors and indirectly stimulating β-receptors, which can significantly reduce peripheral vascular resistance, increase peripheral blood volume, and improve microcirculation. Phentolamine mesylate has an excitatory effect on the heart, increasing myocardial contractility, accelerating heart rate, and increasing cardiac output.
[0004] At present, the dosage forms listed at home and abroad include tablets, injections, capsules, lyophilized powder for injection, granules, etc., which are usually administered orally or by injection. Phentolamine mesylate is a white or off-white crystalline powder that is easily soluble in water or ethanol. It is suitable for development into a liquid preparation from the perspective of dosage form. In addition, there are many clinical experiences in the use of phentolamine mesylate injection by atomization beyond the instructions in China, especially in the field of pediatrics for the treatment of severe pneumonia in children. The use of off-instructions should follow the principle of "off-instructions medication", and more attention should be paid to the adverse reactions caused by the drug, and appropriate drug prescriptions should be selected to ensure the effectiveness and safety of the drug. The existing phentolamine mesylate injection on the market has not undergone rigorous pharmaceutical research on inhalation preparations, and may cause adverse reactions such as mucosal damage and airway spasm after atomization inhalation. Therefore, it is necessary to develop an effective and stable phentolamine mesylate inhalation liquid preparation that can ensure the safety and compliance of patient medication to meet urgent clinical needs. Summary of the invention
[0005] In view of the above problems existing in the prior art, the technical problem to be solved by the present invention is to provide a stable phentolamine mesylate inhalation liquid preparation, which does not contain preservatives commonly used in injection solutions, thereby reducing the adverse reaction rate of medication; another technical problem to be solved by the present invention is to provide a preparation method of the above phentolamine mesylate inhalation liquid preparation, which has good reproducibility of the preparation process, small batch-to-batch variability, and can better realize commercial large-scale production.
[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0007] A stable phentolamine mesylate inhalation liquid preparation is composed of an active component and pharmaceutical excipients; the active component is phentolamine mesylate, and the pharmaceutical excipients include an isotonic agent, a metal ion complex, a pH regulator, and a solvent.
[0008] Preferably, the mass volume concentration g / mL of the active ingredient phentolamine mesylate is 0.05 to 10%. More preferably, the mass volume concentration g / mL of the active ingredient phentolamine mesylate is 0.05 to 5%. Further preferably, the mass volume concentration g / mL of the active ingredient phentolamine mesylate is 0.07 to 2%. Most preferably, the mass volume concentration g / mL of the active ingredient phentolamine mesylate is 1%.
[0009] Preferably, the mass volume concentration g / mL of the isotonic agent is 1% to 10%; more preferably, the mass volume concentration g / mL of the isotonic agent is 2 to 8%; further preferably, the mass volume concentration g / mL of the isotonic agent is 3.5 to 6.5%; most preferably, the mass volume concentration g / mL of the isotonic agent is 5%.
[0010] Preferably, the mass volume concentration g / mL of the metal ion complex is 0.01 to 1%; more preferably, the mass volume concentration g / mL of the metal ion complex is 0.015 to 0.085%; further preferably, the mass volume concentration g / mL of the metal ion complex is 0.35 to 0.7%; most preferably, the mass volume concentration g / mL of the isotonic agent is 0.5%.
[0011] Preferably, the pH adjuster adjusts the pH value to 3 to 5. More preferably, the pH adjuster adjusts the pH value to 3.8 to 4.2.
[0012] Preferably, the isotonic agent is selected from one or a mixture of mannitol, sodium chloride, potassium chloride, glucose, and more preferably, the isotonic agent is selected from mannitol.
[0013] Preferably, the metal complex is selected from ethylenediaminetetraacetic acid and / or ethylenediaminetetraacetic acid salts.
[0014] Preferably, the EDTA salt is selected from one or more of EDTA disodium, EDTA calcium sodium and EDTA iron sodium. More preferably, the EDTA salt is selected from EDTA disodium.
[0015] Preferably, the pH regulator is selected from one or a mixture of hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, acetic acid, sodium acetate, malic acid, citric acid, and sodium hydroxide. More preferably, the pH regulator is selected from a mixture of acetic acid and sodium acetate.
[0016] Preferably, the solvent is selected from any one of physiological saline and water for injection. More preferably, the solvent is selected from water for injection.
[0017] A method for preparing the stable phentolamine mesylate inhalation liquid preparation comprises the following steps:
[0018] 1) taking 80% of the prepared amount of solvent, adding the prescribed amount of isotonic agent and metal ion complex, stirring and dissolving, and after complete dissolution, adding the prescribed amount of phentolamine mesylate and stirring until complete dissolution, to obtain solution A;
[0019] 2) adding a pH adjuster to the obtained solution A, stirring to dissolve, adjusting the pH to 3-5, and adding a solvent to make up the volume to obtain a solution B;
[0020] 3) The obtained solution B is filtered through 0.45 μm and 0.22 μm sterilizing filter membranes in sequence, and sealed in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
[0021] Preferably, the method for preparing the stable phentolamine mesylate liquid preparation for inhalation is carried out under a sterile environment.
[0022] The method for preparing the stable phentolamine mesylate inhalation liquid preparation can prepare the phentolamine mesylate inhalation liquid preparation.
[0023] Beneficial effects: Compared with the prior art, the present invention has the following advantages:
[0024] (1) The present invention adopts atomization inhalation administration to enable phentolamine mesylate to directly enter the airway, with a high concentration in the local respiratory tract, thus achieving targeted and efficient treatment, and with a small dosage and high inhalation rate, significantly improving the patient's compliance;
[0025] (2) In the preparation of the phentolamine mesylate inhalation liquid preparation, the present invention uses multiple membrane filtrations to avoid high-temperature steam sterilization, and adds metal ion complexes, which significantly improves the drug quality and storage stability;
[0026] (3) The phentolamine mesylate inhalation liquid preparation provided by the present invention does not contain preservatives commonly used in injection solutions, thereby reducing the adverse reaction rate of medication and enabling commercial large-scale production. DETAILED DESCRIPTION
[0027] The present invention will be further illustrated below in conjunction with specific examples. The examples are implemented under the premise of the technical solution of the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. If specific conditions are not specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0028] Example 1
[0029] 1. The specific components and dosage are shown in Table 1 below.
[0030] Table 1 Prescription of phentolamine mesylate inhalation liquid preparation
[0031]
[0032] 2. Preparation process: Add 800mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescription amount of mannitol and disodium edetate in sequence, stir and dissolve, after complete dissolution, add phentolamine mesylate and stir until completely dissolved, then add pH adjuster into the solution, stir and dissolve, adjust pH to 4.0, add water for injection to 1000mL, filter through 0.45μm and 0.22μm sterilizing filter membranes, and fill in medical control bottles under nitrogen protection to obtain phentolamine mesylate inhalation liquid preparation.
[0033] Example 2
[0034] 1. The specific components and dosage are shown in Table 2 below.
[0035] Table 2 Prescription of phentolamine mesylate inhalation liquid preparation
[0036]
[0037] 2. Preparation process: Add 800mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescription amount of mannitol and disodium edetate in sequence, stir and dissolve, after complete dissolution, add phentolamine mesylate and stir until completely dissolved, then add pH adjuster into the solution, stir and dissolve, adjust pH to 4.1, add water for injection to 1000mL, filter through 0.45μm and 0.22μm sterilizing filter membranes, and fill in medical control bottles under nitrogen protection to obtain phentolamine mesylate inhalation liquid preparation.
[0038] Example 3
[0039] 1. The specific components and dosage are shown in Table 3 below.
[0040] Table 3 Prescription of phentolamine mesylate inhalation liquid preparation
[0041]
[0042] 2. Preparation process: Add 800 mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescription amount of mannitol and disodium edetate in sequence, stir and dissolve, after complete dissolution, add phentolamine mesylate and stir until completely dissolved, then add a pH adjuster to the solution, stir and dissolve, adjust the pH to 3.8, add water for injection to 1000 mL, filter through 0.45 μm and 0.22 μm sterilizing filter membranes, and fill and seal in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
[0043] Example 4
[0044] 1. The specific components and dosage are shown in Table 4 below.
[0045] Table 4 Phentolamine mesylate inhalation liquid preparation prescription
[0046]
[0047] 2. Preparation process: Add 800 mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescription amount of mannitol and disodium edetate in sequence, stir and dissolve, and after complete dissolution, add phentolamine mesylate and stir until completely dissolved, then add a pH adjuster to the solution, stir and dissolve, adjust the pH to 3.5, add water for injection to 1000 mL, filter through 0.45 μm and 0.22 μm sterilizing filter membranes, and fill and seal in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
[0048] Example 5
[0049] 1. The specific components and dosage are shown in Table 5 below.
[0050] Table 5 Prescription of phentolamine mesylate inhalation liquid preparation
[0051]
[0052] 2. Preparation process: Add 800 mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescription amount of mannitol and disodium edetate in sequence, stir and dissolve, and after complete dissolution, add phentolamine mesylate and stir until completely dissolved, then add a pH adjuster to the solution, stir and dissolve, adjust the pH to 4.2, add water for injection to 1000 mL, filter through 0.45 μm and 0.22 μm sterilizing filter membranes, and fill and seal in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
[0053] Example 6
[0054] 1. The specific components and dosage are shown in Table 6 below.
[0055] Table 6 Phentolamine mesylate inhalation liquid preparation prescription
[0056]
[0057] 2. Preparation process: Add 800 mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescription amount of glucose and disodium edetate in sequence, stir and dissolve, after complete dissolution, add phentolamine mesylate and stir until completely dissolved, then add a pH adjuster to the solution, stir and dissolve, adjust the pH to 4.1, add water for injection to 1000 mL, filter through 0.45 μm and 0.22 μm sterilizing filter membranes, and fill and seal in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
[0058] Comparative Example 1
[0059] 1. The specific components and dosage are shown in Table 7 below.
[0060] Table 7 Phentolamine mesylate inhalation liquid preparation prescription
[0061]
[0062] Process: Add 800mL (80% of the prescription amount) of water for injection into the liquid preparation tank, add the prescribed amount of mannitol, and after it is completely dissolved, add phentolamine mesylate and stir until it is completely dissolved, then add a pH adjuster into the solution, stir to dissolve, adjust the pH to 4.0, add water for injection to 1000mL, filter through 0.45μm and 0.22μm sterilizing filter membranes, and seal in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
[0063] Experimental Example 7
[0064] The samples of Examples 1-6 and Comparative Example 1 were removed from their outer packaging and placed in a constant temperature and humidity chamber at 40±2°C and RH75±5% for 30 days to investigate their stability. Samples were taken at 0, 10, and 30 days to test their properties, contents, and related substances. The test results are shown in Table 8 below.
[0065] Table 8 Properties, contents and related substances data of samples under high temperature test
[0066]
[0067]
[0068]
[0069] The relevant substances are shown in Table 9 below:
[0070] Table 9 Related substances detected
[0071]
[0072] As shown in Table 8, compared with Comparative Example 1, the phentolamine mesylate inhalation liquid preparations in Examples 1-6 were placed in a constant temperature and humidity chamber at a high temperature of 40±2°C and a humidity of RH75±5% for 1 month, and the properties, contents, and related substances were all within the limits, indicating that the phentolamine mesylate inhalation preparations prepared by the present invention have stable properties and reliable quality, and Example 1 has the best effect.
[0073] Experimental Example 8
[0074] The samples of Examples 1-6 and Comparative Example 1 were removed from their outer packaging and placed at room temperature for 30 days. The delivery rate, total delivery amount, and fine particle dosage were then measured. The results are shown in Table 10.
[0075] Delivery rate and total delivery amount: determined according to the method of the "Chinese Pharmacopoeia" (2020 edition).
[0076] Fine particle dosage: Check according to the method for determining the aerodynamic characteristics of fine particles of inhalation preparations (General Rule 0951) of the Chinese Pharmacopoeia (2020 edition).
[0077] Table 10 Delivery rate, total delivery amount, and fine particle dose measurement results
[0078] Sample name Delivery rate (mg / min) Total amount delivered (mg) Fine particle dose (mg) Example 1 1.0 5.0 4.6 Example 2 1.0 4.8 4.4 Example 3 1.0 4.9 4.5 Example 4 0.9 4.8 4.3 Example 5 1.0 4.7 4.4 Example 6 0.9 4.8 4.3 Comparative Example 1 0.8 3.5 2.9
[0079] It can be seen from Table 10 that compared with Comparative Example 1, the products prepared in Examples 1-6 have higher delivery rates, total delivery amounts and fine particle doses after 30 days, indicating that the products in Examples 1-6 have good inhalation performance and can meet clinical use requirements.
[0080] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A stable phentolamine mesylate inhalation liquid preparation, characterized in that: The invention is composed of active components and pharmaceutical excipients; the active component is phentolamine mesylate, and the pharmaceutical excipients include isotonic agent, metal ion complex, pH regulator and solvent.
2. The stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The mass volume concentration g / mL of the active component phentolamine mesylate is 0.05-10%.
3. The stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The mass volume concentration g / mL of the isotonic agent is 1% to 10%, the mass volume concentration g / mL of the metal ion complex is 0.01 to 1%, and the pH adjuster adjusts the pH value to 3 to 5.
4. The stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The isotonic agent is selected from one or a mixture of mannitol, sodium chloride, potassium chloride and glucose.
5. The stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The metal complex is selected from ethylenediaminetetraacetic acid and / or ethylenediaminetetraacetic acid salts.
6. The stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The pH regulator is selected from one of hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, acetic acid, sodium acetate, malic acid, and citric acid, or a mixture of several of them.
7. The stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The solvent is selected from any one of physiological saline and water for injection.
8. A method for preparing the stable phentolamine mesylate inhalation liquid preparation according to claim 1, characterized in that: The following steps are involved: 1) taking 80% of the prepared amount of solvent, adding the prescribed amount of isotonic agent and metal ion complex, stirring and dissolving, and after complete dissolution, adding the prescribed amount of phentolamine mesylate and stirring until complete dissolution, to obtain solution A; 2) adding a pH adjuster to the obtained solution A, stirring to dissolve, adjusting the pH to 3-5, and adding a solvent to make up the volume to obtain a solution B; 3) The obtained solution B is filtered through 0.45 μm and 0.22 μm sterilizing filter membranes in sequence, and sealed in a medical control bottle under nitrogen protection to obtain a phentolamine mesylate inhalation liquid preparation.
9. The method for preparing the stable phentolamine mesylate liquid inhalation preparation according to claim 8, wherein the phentolamine mesylate liquid inhalation preparation is prepared.
